Select Page

For more than 20 years, the Clinique médicale l’Actuel, under the direction of Dr. Réjean Thomas, has been bringing together healthcare professionals, with a focus in virology, to learn from guest experts and discuss the most relevant clinical practice challenges facing them today.

Optimal use of integrate inhibitors in the treatment of HIV

with Dr. Daniel Murphy and Dr. Mark Wainberg



  • Optimal use of integrase inhibitors in the treatment of HIV
  • Why integrase inhibitors should be used as first-line agents
  • Why insist on using a single-pill treatment, at all cost?
  • What are resistance, drug-resistance transmission and cross-resistance?

This activity is supported by
an educational grant from:

ViiV Healthcare



In this program, Dr. Daniel Murphy sits down with Dr. Mark Wainberg to discuss the optimal use of integrase inhibitors in the treatment of HIV. Dr. Wainberg discusses why, according to him, integrase inhibitors should be used as first-line agents instead of rescue medication and the pertinence on insisting on a single-pill treatment.

He also talks about drug resistance, drug-resistance transmission and cross-resistance and why dolutegravir should be used as a first-line treatment for all.

Daniel Murphy, MD

Daniel Murphy, MD


Clinique médicale l’Actuel:
Centre of Excellence HIV – STI – Hepatitis
Affiliated with the Centre hospitalier de l’Université de Montréal (CHUM)
Québec, Canada

Mark A. Wainberg, PhD

Mark A. Wainberg, PhD


HIV/AIDS Research Centre
Professor of medicine
McGill University
Montréal, Québec, Canada


You must be logged in to view the complete program

ViroChannel has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Daniel Murphy, MD has a financial interest/relationship or affiliation in the form of: Consultant: AbbVie, Bristol-Myers Squibb, Janssen, Gilead, Merck, ViiV Healthcare.

Mark Wainberg, PhD has a financial interest/relationship or affiliation in the form of: Industry funded research/investigator and Speakers Bureau, Faculty, Peer Reviewer Advisory Committee/Board: ViiV Healthcare Consultant: Merck, Gilead

Disclosure of Unlabeled Use The faculty of this educational activity may include discussions of products that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses. No responsibility is taken for errors or omissions. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.